Caplin Point Laboratories has delivered exceptional returns with the stock surging 20.25% over the last five trading sessions, according to reports from Business Standard. The pharmaceutical company extended its winning streak to a fifth consecutive session on Tuesday, with shares closing at ₹2,374.45, up 5.18%. The stock has demonstrated strong momentum across multiple timeframes, gaining 28.03% in one month, 41.16% in three months, and 32.28% so far in 2026. As reported by Business Standard, the company is a fully integrated pharmaceutical firm with a strong presence in Latin America. With a decisive surge to ₹2,405.4 on June 10, 2026, the stock has reached a fresh 52-week high, outperforming the broader market significantly.
The company reported robust financial performance for Q4 FY26, as detailed by Business Standard. Consolidated net profit increased 19.32% to ₹170.11 crore compared with ₹142.57 crore in Q4 FY25. Revenue from operations rose 19.45% to ₹600.16 crore from ₹502.43 crore a year earlier. According to the report, for FY26, emerging markets comprising Latin America and Africa contributed 79% of revenue, while the US market accounted for the remaining 21%. The company's growth trajectory shows consistent improvement with YoY growth in nine months ended December 2025 at 19.66% versus 17.36% in December 2024, and annual growth in FY26 at 19.57% versus 17.33% in FY25.
Recent regulatory developments have strengthened the company's US market presence, as reported by Business Standard. Last month, Caplin Steriles, a subsidiary of the company, received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Foscarnet Sodium Injection (6000 mg/250 mL Infusion Bag). The antiviral drug is used to treat CMV retinitis in AIDS patients and HSV infections in immunocompromised individuals. According to IQVIA data, the product recorded US sales of around $15 million in the 12 months ended March 2026.
The stock's exceptional performance has been driven by a combination of strong fundamentals and technical momentum. On June 9, 2026, Caplin Point Laboratories outpaced the broader market with a 7.52% gain, reaching an intraday high of ₹2,281, highlighting a distinctly stock-specific rally rather than a market-wide lift. The 6.72 percentage-point outperformance over the Pharmaceuticals & Biotechnology sector demonstrates the stock's attractiveness to investors. The company has also announced a 200% dividend with ex-date of May 29, 2026, reflecting confidence in its financial position and commitment to shareholder returns.
